… have been reported in patients with existing cardiac disease especially reduced left ventricular function, severe bradycardia or severe hypotension. Careful monitoring of renal function is advised.
Diltiazem is considered unsafe in patients with acute porphyria.
Prior to general anaesthesia, the anaesthetist must be informed of ongoing diltiazem treatment. Depression of cardiac contractility, conductivity and automaticity, as well as the vascular dilatation …
Identical in both labels. Surrounding text shown from Napp Pharmaceuticals Limited.
… ith preexisting bronchial hyper-reactivity. Cases have also been reported after dose increase. Patients should be monitored for signs and symptoms of respiratory impairment during diltiazem therapy.
Diltiazem in considered unsafe in patients with acute porphyria.
Residues from slow-release formulations of the product may pass into the patient's stools; however, this finding has no clinical relevance.
Caution should be exercised when direct oral anticoagulan …